Safety and efficacy profile of first-in-class oral p53 reactivator rezatapopt
1. In this phase 1-2 single-group trial, the p53 reactivator rezatapopt was well-tolerated in adults with solid tumors harboring the...
1. In this phase 1-2 single-group trial, the p53 reactivator rezatapopt was well-tolerated in adults with solid tumors harboring the...
1. In this phase 1-2 randomized controlled trial involving adults with myotonic dystrophy type 1, del-desiran was well-tolerated in most...
1. In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete response...
1. In this randomized controlled trial of adults with central retinal artery occlusion, tenecteplase administration shortly after symptom onset did...
1. This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to...
1. In this randomized controlled trial involving pediatric patients, fremanezumab led to greater reductions in the number of migraine days...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.